[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584126":3},{"organization":4,"outcomesModule":7,"designInfo":73,"detailedDescription":79,"studyPopulation":72,"armGroups":80,"interventions":87,"overallOfficials":72,"centralContacts":93,"locations":99,"responsibleParty":367,"collaborators":369,"id":372,"slug":72,"hasResults":373,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":72,"eligibilityCriteria":377,"healthyVolunteers":373,"sex":378,"minAge":379,"maxAge":72,"enrollmentInfo":380,"targetDuration":72,"studyType":383,"phases":384,"briefSummary":376,"conditions":387,"keywords":72,"overallStatus":102,"whyStopped":72,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":399},{"fullName":5,"class":6},"Zai Lab (Hong Kong), Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":72},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Incidence of Treatment Emergent Adverse-Events in Phase 1b","Number of subjects with treatment-emergent adverse events (TEAEs)","up to 31 months",{"measure":14,"description":15,"timeFrame":12},"Incidence of Serious Adverse Events in Phase 1b","Number of subjects with serious adverse events (SAEs)",{"measure":17,"description":18,"timeFrame":12},"Evaluate antitumor activity of ZL-1310 as a single agent in Phase 2","Confirmed objective response rate (ORR) determined by blinded independent central review (BICR) in Phase 2",[20,23,26,28,30,33,36,39,42,45,47,49,52,54,57,60,63,66,69],{"measure":21,"description":22,"timeFrame":12},"Evaluate preliminary antitumor activity of ZL-1310 as a single agent in Phase 1b","1. BICR-determined confirmed ORR in Phase 1b\n2. Investigator-determined confirmed ORR in Phase 1b",{"measure":24,"description":25,"timeFrame":12},"Evaluate preliminary antitumor activity of ZL-1310 as a single agent in Phase 2","Investigator-determined confirmed ORR in Phase 2",{"measure":27,"description":11,"timeFrame":12},"Incidence of Treatment Emergent Adverse-Events in Phase 2",{"measure":29,"description":15,"timeFrame":12},"Incidence of Serious Adverse Events in Phase 2",{"measure":31,"description":32,"timeFrame":12},"Pharmacokinetics (PK): Time to maximum concentration (Tmax) of Total Antibody in all phases","Time to maximum concentration (Tmax) is a pharmacokinetic parameter that refers to the time it takes for a drug or substance to reach its highest concentration in the bloodstream or a specific body compartment after administration",{"measure":34,"description":35,"timeFrame":12},"Pharmacokinetics (PK): maximum concentration (Cmax) of Total Antibody in all phases","Maximum concentration (Cmax) is a key pharmacokinetic parameter. It represents the highest concentration of a drug or substance that is achieved in the bloodstream or a specific biological fluid or tissue after administration",{"measure":37,"description":38,"timeFrame":12},"Pharmacokinetics (PK): area under the concentration-time curve (AUC) of Total Antibody in all phases","Area under the concentration-time curve (AUC) is a pharmacokinetic parameter that quantitatively describes the total exposure of a drug in the body over a specific period of time",{"measure":40,"description":41,"timeFrame":12},"Pharmacokinetics (PK): apparent clearance (CL) of Total Antibody in all phases","Apparent clearance (CL) is a pharmacokinetic parameter that describes the rate at which a drug is removed from the body relative to the drug's concentration in the bloodstream or a specific body fluid",{"measure":43,"description":44,"timeFrame":12},"Pharmacokinetics (PK): terminal elimination half-life (T1\u002F2) of Total Antibody in all phases","Terminal elimination half-life (T1\u002F2) is a pharmacokinetic parameter that characterizes the time it takes for the concentration of a drug in the body to decrease by half during the terminal phase of drug elimination",{"measure":46,"description":32,"timeFrame":12},"Pharmacokinetics (PK): time to maximum concentration (Tmax) of Unconjugated payloads in all phases",{"measure":48,"description":35,"timeFrame":12},"Pharmacokinetics (PK): maximum concentration (Cmax) of Unconjugated payloads in all phases",{"measure":50,"description":51,"timeFrame":12},"Pharmacokinetics (PK): area under the concentration-time curve (AUC) of Unconjugated payloads in all phases","The area under the concentration - time curve (AUC) is a pharmacokinetic parameter that quantitatively describes the total exposure of a drug in the body over a specific period of time",{"measure":53,"description":41,"timeFrame":12},"Pharmacokinetics (PK): apparent clearance (CL) of Unconjugated payloads in all phases",{"measure":55,"description":56,"timeFrame":12},"Pharmacokinetics (PK): terminal elimination half-life (T1\u002F2) of unconjugated payloads in all phases","Terminal elimination half - life (T1\u002F2) is a pharmacokinetic parameter that characterizes the time it takes for the concentration of a drug in the body to decrease by half during the terminal phase of drug elimination",{"measure":58,"description":59,"timeFrame":12},"Assess immunogenicity of ZL-1310 in all phases","Incidence of anti-drug antibodies (ADAs) to ZL-1310 in all phases",{"measure":61,"description":62,"timeFrame":12},"Evaluate stability and control of disease in all phases","BICR- and investigator-determined disease control rate (DCR) in all phases",{"measure":64,"description":65,"timeFrame":12},"Evaluate durability of response in all phases","BICR- and investigator-determined duration of response (DOR) in all phases",{"measure":67,"description":68,"timeFrame":12},"Evaluate progression-free survival (PFS) in all phases","BICR- and investigator-determined PFS in all phases",{"measure":70,"description":71,"timeFrame":12},"Evaluate survival in all phases","Overall survival (OS) in all phases",null,{"allocation":74,"interventionModel":75,"interventionModelDescription":72,"primaryPurpose":76,"observationalModel":72,"timePerspective":72,"maskingInfo":77},"NA","SINGLE_GROUP","TREATMENT",{"masking":78,"maskingDescription":72,"whoMasked":72},"NONE","This is an open-label, multiple-center, phase 1b\u002F2 study of ZL-1310 in selected solid tumors.",[81],{"label":82,"type":83,"description":84,"interventionNames":85},"Single Arm","EXPERIMENTAL","ZL-1310 as a single agent",[86],"Drug: ZL-1310",[88],{"type":89,"name":90,"description":91,"armGroupLabels":92,"otherNames":72},"DRUG","ZL-1310","drug ZL-1310",[82],[94],{"name":95,"role":96,"phone":97,"phoneExt":72,"email":98},"ZaiLab_1310-002_StudyTeam","CONTACT","86 021-61632588","Zailab_1310-002_StudyTeam@zailaboratory.com",[100,117,130,143,155,168,181,194,207,219,231,244,256,271,280,293,306,315,328,341,354],{"facility":101,"status":102,"city":103,"state":104,"zip":105,"country":106,"countryCode":107,"cosmosGeoPoint":108,"geoPoint":113,"contacts":114},"Zai Lab Site 2001","RECRUITING","San Francisco","California","94143","United States","US",{"type":109,"coordinates":110},"Point",[111,112],-122.41942,37.77493,{"lat":112,"lon":111},[115],{"name":116,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 2001",{"facility":118,"status":102,"city":119,"state":120,"zip":121,"country":106,"countryCode":107,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Zai Lab Site 2015","Peoria","Illinois","61637",{"type":109,"coordinates":123},[124,125],-89.58899,40.69365,{"lat":125,"lon":124},[128],{"name":129,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 2015",{"facility":131,"status":102,"city":132,"state":133,"zip":134,"country":106,"countryCode":107,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Zai Lab Site 2013","Detroit","Michigan","48201",{"type":109,"coordinates":136},[137,138],-83.04575,42.33143,{"lat":138,"lon":137},[141],{"name":142,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 2013",{"facility":144,"status":102,"city":145,"state":145,"zip":146,"country":106,"countryCode":107,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Zai Lab Site 2002","New York","10065",{"type":109,"coordinates":148},[149,150],-74.00597,40.71427,{"lat":150,"lon":149},[153],{"name":154,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 2002",{"facility":156,"status":102,"city":157,"state":158,"zip":159,"country":106,"countryCode":107,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"Zai Lab Site 2024","Cleveland","Ohio","44106",{"type":109,"coordinates":161},[162,163],-81.69541,41.4995,{"lat":163,"lon":162},[166],{"name":167,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 2024",{"facility":169,"status":102,"city":170,"state":171,"zip":172,"country":106,"countryCode":107,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"Zai Lab Site 2004","Philadelphia","Pennsylvania","19111",{"type":109,"coordinates":174},[175,176],-75.16362,39.95238,{"lat":176,"lon":175},[179],{"name":180,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 2004",{"facility":182,"status":102,"city":183,"state":184,"zip":185,"country":106,"countryCode":107,"cosmosGeoPoint":186,"geoPoint":190,"contacts":191},"Zai Lab Site 2014","Nashville","Tennessee","37203",{"type":109,"coordinates":187},[188,189],-86.78444,36.16589,{"lat":189,"lon":188},[192],{"name":193,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 2014",{"facility":195,"status":102,"city":196,"state":197,"zip":198,"country":106,"countryCode":107,"cosmosGeoPoint":199,"geoPoint":203,"contacts":204},"Zai Lab Site 2003","Dallas","Texas","75246",{"type":109,"coordinates":200},[201,202],-96.80667,32.78306,{"lat":202,"lon":201},[205],{"name":206,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 2003",{"facility":208,"status":102,"city":209,"state":197,"zip":210,"country":106,"countryCode":107,"cosmosGeoPoint":211,"geoPoint":215,"contacts":216},"Zai Lab Site 2007","Houston","77030",{"type":109,"coordinates":212},[213,214],-95.36327,29.76328,{"lat":214,"lon":213},[217],{"name":218,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 2007",{"facility":220,"status":102,"city":221,"state":197,"zip":222,"country":106,"countryCode":107,"cosmosGeoPoint":223,"geoPoint":227,"contacts":228},"Zai Lab Site 2011","McAllen","78503",{"type":109,"coordinates":224},[225,226],-98.23001,26.20341,{"lat":226,"lon":225},[229],{"name":230,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 2011",{"facility":232,"status":102,"city":233,"state":234,"zip":235,"country":106,"countryCode":107,"cosmosGeoPoint":236,"geoPoint":240,"contacts":241},"Zai Lab Site 2006","Fairfax","Virginia","22031",{"type":109,"coordinates":237},[238,239],-77.30637,38.84622,{"lat":239,"lon":238},[242],{"name":243,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 2006",{"facility":245,"status":102,"city":246,"state":234,"zip":247,"country":106,"countryCode":107,"cosmosGeoPoint":248,"geoPoint":252,"contacts":253},"Zai Lab Site 2012","Norfolk","23502",{"type":109,"coordinates":249},[250,251],-76.28522,36.84681,{"lat":251,"lon":250},[254],{"name":255,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 2012",{"facility":257,"status":102,"city":258,"state":259,"zip":260,"country":261,"countryCode":262,"cosmosGeoPoint":263,"geoPoint":267,"contacts":268},"Zai Lab Site 1002","Beijing","Beijing Municipality","100142","China","CN",{"type":109,"coordinates":264},[265,266],116.39723,39.9075,{"lat":266,"lon":265},[269],{"name":270,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 1002",{"facility":272,"status":102,"city":258,"state":259,"zip":273,"country":261,"countryCode":262,"cosmosGeoPoint":274,"geoPoint":276,"contacts":277},"Zai Lab Site 1013","102200",{"type":109,"coordinates":275},[265,266],{"lat":266,"lon":265},[278],{"name":279,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 1013",{"facility":281,"status":102,"city":282,"state":283,"zip":284,"country":261,"countryCode":262,"cosmosGeoPoint":285,"geoPoint":289,"contacts":290},"Zai Lab Site 1009","Xiamen","Fujian","361003",{"type":109,"coordinates":286},[287,288],118.08187,24.47979,{"lat":288,"lon":287},[291],{"name":292,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 1009",{"facility":294,"status":102,"city":295,"state":296,"zip":297,"country":261,"countryCode":262,"cosmosGeoPoint":298,"geoPoint":302,"contacts":303},"Zai Lab Site 1016","Guangzhou","Guangdong","510030",{"type":109,"coordinates":299},[300,301],113.25,23.11667,{"lat":301,"lon":300},[304],{"name":305,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 1016",{"facility":307,"status":102,"city":295,"state":296,"zip":308,"country":261,"countryCode":262,"cosmosGeoPoint":309,"geoPoint":311,"contacts":312},"Zai Lab Site 1004","510080",{"type":109,"coordinates":310},[300,301],{"lat":301,"lon":300},[313],{"name":314,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 1004",{"facility":316,"status":102,"city":317,"state":318,"zip":319,"country":261,"countryCode":262,"cosmosGeoPoint":320,"geoPoint":324,"contacts":325},"Zai Lab Site 1012","Harbin","Heilongjiang","150081",{"type":109,"coordinates":321},[322,323],126.65,45.75,{"lat":323,"lon":322},[326],{"name":327,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 1012",{"facility":329,"status":102,"city":330,"state":331,"zip":332,"country":261,"countryCode":262,"cosmosGeoPoint":333,"geoPoint":337,"contacts":338},"Zai Lab Site 1006","Changsha","Hunan","410013",{"type":109,"coordinates":334},[335,336],112.97087,28.19874,{"lat":336,"lon":335},[339],{"name":340,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 1006",{"facility":342,"status":102,"city":343,"state":344,"zip":345,"country":261,"countryCode":262,"cosmosGeoPoint":346,"geoPoint":350,"contacts":351},"Zai Lab Site 1008","Changchun","Jilin","130012",{"type":109,"coordinates":347},[348,349],125.32278,43.88,{"lat":349,"lon":348},[352],{"name":353,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 1008",{"facility":355,"status":102,"city":356,"state":357,"zip":358,"country":261,"countryCode":262,"cosmosGeoPoint":359,"geoPoint":363,"contacts":364},"Zai Lab Site 1001","Shanghai","Shanghai Municipality","200000",{"type":109,"coordinates":360},[361,362],121.45806,31.22222,{"lat":362,"lon":361},[365],{"name":366,"role":96,"phone":72,"phoneExt":72,"email":72},"Site 1001",{"type":368,"investigatorFullName":72,"investigatorTitle":72,"investigatorAffiliation":72,"oldNameTitle":72,"oldOrganization":72},"SPONSOR",[370],{"name":371,"class":6},"Zai Lab (US) LLC","100584126",false,"NCT06885281","A Study of ZL-1310 in Participants With Selected Solid Tumors","A Phase 1b\u002F2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors","Inclusion Criteria:\n\n* Signed informed consent\n* Adult men and women ≥18 years of age\n* Participants must have histologically confirmed, locally advanced or metastatic NeuroEndocrine Carcionomas (NEC), and must have experienced disease progression on or after platinum-based therapy\n* Participants must be willing to undergo a tumor biopsy or must provide archived tumor tissue sample\n* Participants must have at least one measurable target lesion as defined by RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Life expectancy ≥ 3 months\n\nExclusion Criteria:\n\n* Participants with another known malignancy that is progressing or requires active treatment within the last 2 years\n* Clinically active central nervous system (CNS) metastases\n* Participants with leptomeningeal metastasis\n* Participants who have received any ADC with a payload of topoisomerase I inhibitor (e.g., exatecan derivative)\n* Treatment with any systemic anti-cancer treatment or other investigational products\u002Fdevice within 3 weeks before the first dose of study treatment\n* Non-palliative radiotherapy within 2 weeks to non-thoracic area or within 4 weeks to the thoracic area prior to first dose of study treatment or a history of radiation pneumonitis\n* Major surgery within 4 weeks of the first dose of study treatment\n* Hypersensitivity to any ingredient of the study treatment\n* Out of range value (as defined in protocol) within 10 days prior to the first dose of study treatment\n* Impaired cardiac function or clinically significant cardiac disease within the last 3 months before administration of the first dose of the study treatment\n* Lung-specific intercurrent clinically significant illnesses and any autoimmune, connective tissue, or inflammatory disorders including but not limited to pneumonitis\n* Has a history of (noninfectious) ILD\u002Fpneumonitis that required steroids, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at Screening\n* Pregnant or nursing (lactating) women\n* Participants who have been on concomitant strong CYP3A or CYP2D6 inhibitors within 14 days or 5 half-lives before the first dose of study treatment, whichever is longer","ALL","18 Years",{"count":381,"type":382},112,"ESTIMATED","INTERVENTIONAL",[385,386],"PHASE1","PHASE2",[388],"Solid Tumors","2026-05-07",{"date":391,"type":392},"2026-05-08","ACTUAL",{"date":394,"type":392},"2025-05-12",{"date":396,"type":382},"2027-12",{"name":398,"class":6},"Zai Lab (Shanghai) Co., Ltd.",21]